Dissertations / Theses on the topic 'HIV Envelope Protein gp160'

Despite 30 years of intensive research，an effective human immunodeficiency virus (HIV) vaccine still remains elusive. The desirable immune response capable of providing protection against HIV acquisition is still not clear. The accumulating evidence learned from a recent vaccine efficacy correlate study not only confirmed the importance of antibody responses, but also highlighted potential protective functions of antibodies with a broad repertoire of HIV-1 epitope specificities and a wide range of different antiviral mechanisms. This necessitates a deep understanding of the complexity and diversity of antibody responses elicited by HIV-1 vaccines. My dissertation characterizes antibody response profiles of HIV-1 Env antibodies elicited by several novel immunogens or different immunization regimens, in terms of magnitude, persistence, epitope specificity, binding affinity, and biological function. First, to overcome the challenge of studying polyclonal sera without established assays, we expanded a novel platform to isolate Env-specific Rabbit mAbs (RmAb) elicited by DNA prime-protein boost immunization. These RmAbs revealed diverse epitope specificity and cross-reactivity against multiple gp120 antigens from more than one subtype, and several had potent and broad neutralizing activities against sensitive Tier 1 viruses. Further, structural analysis of two V3 mAbs demonstrated that a slight shift of the V3 epitope might have a dramatic impact on their neutralization activity. All of these observations provide a useful tool to study the induction of a desired type of antibody by different immunogens or different immunization regimens. Since heavily glycosylated HIV Env protein is a critical component of an HIV vaccine, we wanted to determine the impact of the HIV Env-associated glycan shield on antibody responses. We were able to produce Env proteins with a selective and homogeneous pattern of N-glycosylation using a glycoengineered yeast cell line. Antigenicity of these novel Env proteins was examined by well-characterized human mAbs. Immunogenicity studies showed that they were immunogenic and elicited gp120- specific antibody responses. More significantly, sera elicited by glycan-modified gp120 protein immunogens revealed better neutralizing activities and increased diversity of epitopes compared to sera elicited by traditional gp120 produced in Chinese Hamster Ovary (CHO) cells. Further, we examined the impact of the delivery order of DNA and protein immunization on antibody responses. We found that DNA prime-protein boost induced a comparable level of Env-specific binding Abs at the peak immunogenicity point to codelivery of DNA. However, antibody responses from DNA prime-protein boost had high avidity and diverse specificities, which improved potency and breadth of neutralizing Abs against Tier 1 viruses. Our data indicate that DNA vaccine priming of the immune system is essential for generation of high-quality antibodies. Additionally, we determined the relative immunogenicity of gp120 and gp160 Env in the context of DNA prime-protein boost vaccination to induce high-quality antibody responses. Immunized sera from gp120 DNA primed animals, but not those primed with gp160 DNA, presented with distinct antibody repertoire specificities, a high magnitude of CD4 binding site-directed binding capabilities as well as neutralizing activities. We confirmed the importance of using the gp120 Env form at the DNA priming phase, which directly determined the quality of antibody response.

Despite 30 years of intensive research，an effective human immunodeficiency virus (HIV) vaccine still remains elusive. The desirable immune response capable of providing protection against HIV acquisition is still not clear. The accumulating evidence learned from a recent vaccine efficacy correlate study not only confirmed the importance of antibody responses, but also highlighted potential protective functions of antibodies with a broad repertoire of HIV-1 epitope specificities and a wide range of different antiviral mechanisms. This necessitates a deep understanding of the complexity and diversity of antibody responses elicited by HIV-1 vaccines. My dissertation characterizes antibody response profiles of HIV-1 Env antibodies elicited by several novel immunogens or different immunization regimens, in terms of magnitude, persistence, epitope specificity, binding affinity, and biological function. First, to overcome the challenge of studying polyclonal sera without established assays, we expanded a novel platform to isolate Env-specific Rabbit mAbs (RmAb) elicited by DNA prime-protein boost immunization. These RmAbs revealed diverse epitope specificity and cross-reactivity against multiple gp120 antigens from more than one subtype, and several had potent and broad neutralizing activities against sensitive Tier 1 viruses. Further, structural analysis of two V3 mAbs demonstrated that a slight shift of the V3 epitope might have a dramatic impact on their neutralization activity. All of these observations provide a useful tool to study the induction of a desired type of antibody by different immunogens or different immunization regimens. Since heavily glycosylated HIV Env protein is a critical component of an HIV vaccine, we wanted to determine the impact of the HIV Env-associated glycan shield on antibody responses. We were able to produce Env proteins with a selective and homogeneous pattern of N-glycosylation using a glycoengineered yeast cell line. Antigenicity of these novel Env proteins was examined by well-characterized human mAbs. Immunogenicity studies showed that they were immunogenic and elicited gp120- specific antibody responses. More significantly, sera elicited by glycan-modified gp120 protein immunogens revealed better neutralizing activities and increased diversity of epitopes compared to sera elicited by traditional gp120 produced in Chinese Hamster Ovary (CHO) cells. Further, we examined the impact of the delivery order of DNA and protein immunization on antibody responses. We found that DNA prime-protein boost induced a comparable level of Env-specific binding Abs at the peak immunogenicity point to codelivery of DNA. However, antibody responses from DNA prime-protein boost had high avidity and diverse specificities, which improved potency and breadth of neutralizing Abs against Tier 1 viruses. Our data indicate that DNA vaccine priming of the immune system is essential for generation of high-quality antibodies. Additionally, we determined the relative immunogenicity of gp120 and gp160 Env in the context of DNA prime-protein boost vaccination to induce high-quality antibody responses. Immunized sera from gp120 DNA primed animals, but not those primed with gp160 DNA, presented with distinct antibody repertoire specificities, a high magnitude of CD4 binding site-directed binding capabilities as well as neutralizing activities. We confirmed the importance of using the gp120 Env form at the DNA priming phase, which directly determined the quality of antibody response.

Human immunodeficiency type 1 (HIV-1) is able to elicit broadly potent neutralizing antibodies in a very small subset of individuals only after several years’ infection and as a result, vaccines that elicit these types of antibodies have been difficult to design. The RV144 trial showed that a moderate protection is possible, which may correlate with antibody dependent cellular cytotoxicity (ADCC) activity. Previous studies in the Lu lab demonstrated that in an HIV-1 vaccine phase I trial, DP6-001, a polyvalent Env DNA prime-protein boost formulation, could elicit potent and broadly reactive, gp120-specific antibodies with positive neutralization activities along with multiple Fc mediated effector functions. I developed a protocol for the production and analysis of HIV-1 Env-specific human monoclonal antibodies (mAbs) isolated from these DP6-001 vaccinees. By utilizing a labeled gp120 bait to isolate Env specific B cells, paired heavy and light chain immunoglobulin (Ig) genes were cloned and allowed for the production of monoclonal antibodies with specificity for gp120. By using this protocol, 13 isolated mAbs from four DP6-001 vaccinees showed broad binding activities to gp120 proteins of diverse subtypes, both autologous and heterologous to vaccine immunogens, with mostly conformational epitopes and a few V3 and C5 specific mAbs. Equally cross-reactive Fc-mediated functional activities, including ADCC and antibody dependent cellular phagocytosis (ADCP), were present with both immune sera and isolated mAbs, confirming the induction of non-neutralizing functional antibodies by the DNA prime- protein boost vaccination. Elicitation of broadly reactive mAbs by vaccination in healthy human volunteers confirms the value of the polyvalent formulation in this HIV-1 vaccine design.

Human immunodeficiency type 1 (HIV-1) is able to elicit broadly potent neutralizing antibodies in a very small subset of individuals only after several years’ infection and as a result, vaccines that elicit these types of antibodies have been difficult to design. The RV144 trial showed that a moderate protection is possible, which may correlate with antibody dependent cellular cytotoxicity (ADCC) activity. Previous studies in the Lu lab demonstrated that in an HIV-1 vaccine phase I trial, DP6-001, a polyvalent Env DNA prime-protein boost formulation, could elicit potent and broadly reactive, gp120-specific antibodies with positive neutralization activities along with multiple Fc mediated effector functions. I developed a protocol for the production and analysis of HIV-1 Env-specific human monoclonal antibodies (mAbs) isolated from these DP6-001 vaccinees. By utilizing a labeled gp120 bait to isolate Env specific B cells, paired heavy and light chain immunoglobulin (Ig) genes were cloned and allowed for the production of monoclonal antibodies with specificity for gp120. By using this protocol, 13 isolated mAbs from four DP6-001 vaccinees showed broad binding activities to gp120 proteins of diverse subtypes, both autologous and heterologous to vaccine immunogens, with mostly conformational epitopes and a few V3 and C5 specific mAbs. Equally cross-reactive Fc-mediated functional activities, including ADCC and antibody dependent cellular phagocytosis (ADCP), were present with both immune sera and isolated mAbs, confirming the induction of non-neutralizing functional antibodies by the DNA prime- protein boost vaccination. Elicitation of broadly reactive mAbs by vaccination in healthy human volunteers confirms the value of the polyvalent formulation in this HIV-1 vaccine design.

La gp120 du VIH-1 se fixe aux héparane sulfate (HS) cellulaires, par le biais de la boucle V3 ce qui favorise l'infectivité virale. Cependant, une polyanion solubles (HS12), conjugués à CD4 (mCD4-HS12) a des propriétés antivirales et a montré in vitro une activité contre le VIH-1 à de concentrations nM. En raison de la complexité structurale des HS, le criblage d'oligosaccharides différenciellement sulfatés pour améliorer l'activité de la molécule serait trop difficile. En vue d'obtenir une molécule plus spécifique, de plus haute affinité et plus facile à produire, des peptides mimant les HS ont été synthétisés par nos collaborateurs. Notre but était de cribler ces peptides pour leur capacité à inhiber l'entrée de VIH-1. Nous avons mis en place une plateforme permettant d'immobiliser CCR5 et CXCR4 solubilisés sur des biocapteurs pour cribler des molécules qui inhibent la liaison de gp120-CD4 aux corécepteurs. Pour contrôler le processus de solubilisation, CXCL12, le ligand naturel de CXCR4, a été injecté sur CXCR4 immobilisé. Les affinités des isoformes CXCL12 (α et γ) pour CXCR4 ont été calculées dans les fourchettes de valeurs précédemment décrites avec des techniques différentes prouvant la fonctionnalité de notre système. Nous montrons pour la première fois que les HS régulent différemment les mécanismes de liaison de ces deux isoformes et nous proposons un nouveau mode d'action pour le domaine C-terminal particulièrement basique de CXCL12 γ vis-à-vis de CXCR4. Le système a ensuite été utilisé pour cribler la capacité d'inhibition des peptides mimétiques du HS. Chaque peptide, [S(XDXS)n] contient des acides aminés qui imitent les groupes hydroxyles, carboxyles et sulfates des HS. Le peptide contenant des résidus sulphotyrosines, une fois conjugué à mCD4 (mCD4-P3YSO3), montre un IC50 de l'ordre du nM, pour l'inhibition simultanée de la liaison de gp120 aux HS, à CD4, aux anticorps, aux corécepteurs ainsi que l'infection par VIH-1 in cellulo. Il constitue le premier inhibiteur bivalent de l'entrée qui cible à la fois les virus R5 et X4 et le concept d'un peptide mimétique des HS se prête à une analyse structurale et fonctionnelle de la liaison des chaînes HS aux protéines, une nouvelle technique dans ce domaine.

Avaliou-se a expressão do gene mbl2 em 79 crianças e suas mães HIV positivas com o objetivo de avaliar a sua influência na transmissão vertical. Os pacientes divididos em dois grupos: crianças HIV positivas e suas mães (n=18) e crianças HIV negativas e suas mães (n=61) foram avaliados pelo CH50 e AP50 (ensaios hemolíticos), dosagem e avaliação funcional da MBL, ativação da cascata terminal do complemento (ELISA) e o gene mbl2 (PCR). Os resultados não mostraram diferença significante entre os níveis séricos, atividade funcional e o gene da MBL entre os grupos, excluindo a sua influência sobre a transmissão materno-fetal do HIV
It was evaluated the mbl2 gene expression in 79 children and their HIV positive mothers with the aim to evaluate its influence on mother-to-child HIV. The patients were divided in two groups: HIV positive children and their mothers (n=18) and HIV negative children and their mothers (n=61) were evaluated by CH50 and AP50 (hemolytic assays); levels and functional MBL and terminal complement cascade (ELISA) and mbl2 gene (PCR). The results didn't show significant difference amons serum levels, functional activities and MBL gene between the groups, excluding the influence in the mother-to child HIV transmission.

We postulated that gp120 and CD4 interaction might expose cryptic epitopes on gp120 that could be immunogenic and so widen the immunogenic response. A fusion protein of a C clade strain of HIV-1 (HIVCN54) gp120 and full-length human CD4 was constructed and expressed using a recombinant baculovirus system. The protein was purified, characterized and used to immunize rabbits. The antiserum generated had an expected anti-gp120 activity and demonstrated a higher capacity than a control serum raised to gp120 alone to block b12 binding, a marker of neutralization. A formal neutralization assay however did not detect neutralizing activity in the CD4-gp120CN54 antiserum. To enhance overall immunogenicity, a gp120CN54-FPV168 fusion protein was also expressed. FPV168 is a fowlpox virus protein. Although designed to elicit a stronger host immune response, the antiserum generated to gp120CN54-FPV168 had a weaker binding activity to gp120 than the antiserum generated to non-fused gp120CN54. A possible reason was protein instability associated with fusion to the N-terminus of FPV168. To ameliorate this problem, three gp120 fusion proteins with N-terminal truncated FPV168 were also constructed. The stability of these proteins was vastly improved but their performance as immunogens continued to be poorer than immunization with gp120 alone. Lastly, experiments describing an alternative strategy of immune enhancement based on targeting of gp120 or fragments of gp120 to antigen presenting cells via use of the human immunoglobulin Fc domain are presented. These were more successful and indicate a future direction that could yet produce an HIV-1 gp120 based immunogen capable of raising the antibody responses required as part of a successful vaccine.

The aim of this thesis was firstly to investigate the possibility of local antibody in urine samples from HEPS individuals to evaluate the theory that such individuals may develop a protective local anti-HIV-l antibody response, detectable in urine. Since elicitation of mucosal immunity is important in preventing viral infection by sexual transmission, development of a vaccine which is effective for the induction of mucosal immune responses may provide protection to mucosal surfaces against HIV-1 transmission. Transgenic plants expressing foreign protein has been demonstrated to be an inexpensive and easily delivered system for the production of animal and human vaccines which can effectively induce mucosal immune response. The second aim of this work was to develop a transgenic plant system expressing HIV-1 gp160 protein to exploit the feasibility of HIV-1 oral vaccine. The specificity of IgG, IgA and sIgA anti-HIV antibodies to different HIV-1 viral proteins present in paired urine and serum samples from 3 HIV-1 seropositive and 9 HEPS individuals were profiled using Western blot immunoassay. Specific sIgA antibodies to HIV-1 gpl60, p65, gp4l, p31 and p24 were detected in urine or the corresponding vaginal swab samples from HIV-1 seropositive individuals, which suggested that a local mucosal immune response was induced by HIV-1 infection. For samples from HEPS individuals, specific IgG antibodies to HIV-1 gp160, gpl2O and p51, and IgA antibody to HIV-1 p51 were detected in 1 of 9 urine but not the corresponding serum samples, respectively. These results suggested that local mucosal immune responses may be elicited in those HEPS individuals. Furthermore, IgG are the predominant isotype of anti-HIV antibodies present in the genitourinary tract of those HEPS subjects and may be associated with a natural protection mechanism in some individuals.

La glicoproteïna de l’envolta (Env) és una de les proteïnes claus del VIH-1 en patogènesi. La seqüència del gen env és important per a codificar l’Env però també per les estructures secundàries dels RREs que contenen els seus trànscrits. La rellevància dels dos elements s’ha comprovat extensament, tot i que assajos funcionals són requerits en ambdós casos per estudiar l’impacte de canvis específics. El tractament amb l’inhibidor de fusió T-20 selecciona virus resistents després d’adquirir canvis al gen env. Per estudiar variants funcionalment rellevants d’env que es trobessin in vivo vam decidir utilitzar mutacions associades a T-20. Les prediccions de les estructures secundàries dels RRE van resultar alterades en els canvis que codificaven per G36V/D, V38A, Q40H i L45M, però no per N43D o Q40H-L45M. Funcionalment vam demostrar que només els mutants que presenten el canvi L45M a la seva seqüència pateixen un impacte en la capacitat d’unir-se a la proteïna viral Rev quan aquesta es troba en baixes concentracions, suggerint que els canvis nucleotídics que afecten a la formació de l’aminoàcid 45 de gp41 juguen un paper en la unió a Rev. De totes maneres, ninguna variant d’RRE va ser afectada en la seva capacitat per a ser transportada al citoplasma. Per tant, alteracions en les prediccions d’estructures secundàries a partir de seqüències nucleotídiques no necessàriament impliquen impactes funcionals i la mutació L45M no s’incorpora com a mutació secundària degut a un restaurament de les funcions del RRE. Com que és important caracteritzar funcionalment Envs derivades de pacients per a estudiar la seva patogenicitat, vam establir una metodologia completa per a estudiar-les basant-nos en el paper principal que hi juga la subunitat gp41. Els resultats demostren que la selecció de la línia cel·lular efectora és essencial per optimitzar la sensibilitat dels assajos. La línia cel·lular 293T hauria de ser utilitzada per experiments fusogènics i la HeLa per analitzar paràmetres relacionats amb la mort. Estudis clínics havien suggerit que virus que contenien la mutació V38A i que havien aparegut sota un context que tinguessin el polimorfisme viral N140I eren menys patogènics degut a que estaven associats amb fallada virològica i beneficis immunològics. Per tal d’entendre aquestes dades discordants vam basar-nos en la nostra metodologia per a analitzar Envs derivades de pacients que tinguessin aquests canvis. Aquestes Envs V38A-N140I van resultar tenir menys capacitat per induir la mort per cèl·lula individual tot i no veure’s alterada la seva capacitat fusogènica, remarcant la importància del context de l’Env i el paper central de gp41 a la patogènesi del VIH-1.
La glicoproteína de la envuelta (Env) es una de les proteínas claves del VIH-1 en patogénesis. La secuencia del gen env es importante para codificar la Env pero también para las estructuras secundarias de los RREs presentes en sus tránscritos. La relevancia de estos dos elementos ha sido comprobada extensamente, pese a que ensayos funcionales aún son requeridos en ambos casos para estudiar el impacto de cambios específicos. El tratamiento con el inhibidor de fusión T-20 selecciona virus resistentes después de adquirir cambios en el gen env. Para estudiar variantes funcionalmente relevantes de env que se encontraran in vivo decidimos utilizar mutaciones asociadas a T-20. Las predicciones de las estructuras secundarias de los RRE resultaron alteradas en los cambios que codificaban para G36V/D, V38A, Q40H y L45M, pero no para N43D o Q40H-L45M. Funcionalmente demostramos que sólo los mutantes que presentan el cambio L45M en su secuencia sufren un impacto de unión a la proteína viral Rev cuando ésta se encuentra en bajas concentraciones, sugiriendo que los cambios nucleotídicos que afectan a la formación del aminoácido 45 de gp41 juegan un papel en la unión a Rev. No obstante, la capacidad de transporte al citoplasma de estos RRE no está afectada. Por lo tanto, alteraciones en las estructuras secundarias predictivas a partir de secuencias nucleotídicas no necesariamente implican impactos funcionales y la mutación L45M tampoco se incorpora como mutación secundaria debido a la restauración de las funciones del RRE. Como es importante caracterizar funcionalmente Envs derivadas de pacientes para estudiar su patogenicidad, establecimos una metodología completa basándonos en el papel principal de la subunidad gp41. Los resultados demostraron que la línea celular efectora es esencial para optimizar la sensibilidad de los ensayos. La línea celular 293T debería utilizarse para experimentos de fusión y la HeLa per analizar parámetros de citopaticidad. Estudios clínicos habían sugerido que virus que contenían la mutación V38A y el polimorfismo viral N140I estaban asociados a una fallo virológico y beneficios inmunológicos del paciente debido a que eran menos patogénicos. Para entender estos datos discordantes analizamos Envs derivadas de pacientes y vimos que cuando éstas tenían los cambios V38A-N140I tenían menos capacidad para matar células diana de forma individual pese a no tener alterada su capacidad fusogénica. Estos datos remarcan la importancia del contexto de la Env y el papel central de gp41 en la patogénesis del VIH-1.
The Env glycoprotein is one of the key proteins used by HIV-1 to mediate its pathogenicity. The sequence of the env gene is important to encode the Env glycoprotein but also for the secondary structure of the RRE that harbor its transcripts. The relevance of both elements has been extensively proved, although functional assays were needed in both cases to study the impact of specific changes. Treatment with the fusion inhibitor T-20 in patients infected with HIV-1 select resistant viruses to this drug after acquiring changes in their env gene. Therefore, we decided to use T-20-associated changes in order to functionally study relevant in vivo env variants. Predictions of the RRE secondary structures showed alterations when they were encoding for the changes G36V/D, V38A, Q40H and L45M, but not when harboring N43D and Q40H-L45M. Functional data showed that only the mutants harboring the L45M mutation had impairments in their binding capacity to Rev when this protein was at low concentrations, suggesting that the nucleotide changes affecting the encoding of the amino acid 45 in gp41 plays a role in Rev binding. However, none of the RRE variants were affected in their ability to being transported to the cytoplasm. Thus, it was found that alterations in RRE secondary structures predicted from nucleotide sequences might not necessary imply functional impairments and that the L45M change was not incorporated as a secondary mutation due to a restoration of the RRE functions. As it is important to functionally characterize patient-derived Envs to understand their in vivo pathogenesis, we established a complete methodology to study them by focusing on the main role of the subunit gp41. Based on our results, the correct selection of the effector cell line is essential to optimize the sensitivity of the assays. The 293T cell line might be used for fusogenic experiments and the HeLa for analyzing death parameters. Clinical trials had suggested that V38A viral mutants arising in an Env context containing the N140I polymorphism, were low pathogenic due to they were associated with virological failure and immunologic benefits. In order to understand these in vivo discordant data, we used our complete methodology to analyze patient-derived Envs that harbored these changes. We found that the V38A mutant Envs that were arisen in a N140I context were less able to induce single-cell death to target cells despite not having an altered fusogenic capacity. Thus, these data supports the importance of the Env context and the main role of gp41 in HIV-1 pathogenesis.

Human immunodeficiency virus type 1 (HIV-1) establishes a persistent infection that leads to acquired immunodeficiency syndrome (AIDS). Approximately 36 million people worldwide are living with HIV-1, which is commonly acquired through sexual contact. Antiviral therapies control disease progression, but do not eliminate this virus from the host. Thus, global efforts are focused on developing vaccines that prevent HIV-1 transmission. Such vaccines are based on eliciting the production of protective antibodies that target the envelope glycoproteins (Envs) of this virus. Unfortunately, HIV-1 immunization trials have shown limited efficacy. A better understanding of the antibody-mediated inactivation process is needed to improve vaccine strategies. In this work we describe two novel factors that contribute to HIV-1 inactivation. First, we show that structural stability of the Env protein determines its sensitivity to vaccine-elicited antibodies. Different interactions within Env contribute to its stability. Perturbation of the Env-stabilizing interactions by physical and chemical treatments enhances sensitivity of HIV-1 to antibodies. Second, we found that the chemical composition of the transmission medium affects Env inhibition by antibodies and other inhibitory agents. Semen is the most common vehicle for HIV-1 transmission. This medium contains high concentrations of the sugar fructose. We found that semen fructose competitively blocks binding of antiviral agents that target sugar residues on Env. Together, this work advances our understanding of the mechanism that underlies HIV-1 inactivation by vaccine-elicited antibodies and provides novel strategies to enhance their potency.

Une des caractéristiques du Virus de l’Immunodéficience Humaine de type 1 (VIH-1) est sa diversification génétique extensive, qui lui permet d’échapper au système immunitaire. Néanmoins, il est nécessaire que le taux de mutation requis pour à cette évolution rapide ne compromette pas la fonctionnalité de ses protéines. Les travaux présentés ici ont eu pour objectif l’étude des réseaux de coévolution qui composent les glycoprotéines d’enveloppe (Env) afin de comprendre les règles qui sous-tendent leur évolution. Il a été mis en évidence que les régions variables de ces protéines, grâce à leur flexibilité structurelle, peuvent aussi servir à faciliter l’incorporation de mutations touchant les régions plus constantes. De plus, un réseau de coévolution impliqué dans les changements de conformations nécessaires à l’activité de Env a été identifié, soutenant le fait que ces régions variables ont un rôle central dans ces changements. Ces études démontrent le rôle crucial joué par les régions variables en dévoilant un nouvel aspect de leur contribution à l’évolution du VIH-1
The Human Immunodeficiency Virus type 1 (HIV-1) is characterized by an extensive genetic diversification of its strains that allows the virus to escape the immune system. However, the mutation rate needed for this rapid evolution must not compromise the functionality of the viral proteins. The aim of the work presented here has been to study the coevolution networks that constitute the envelope glycoproteins (Env) in order to understand the rules driving their evolution. The results have highlighted that variable regions, thanks to their structural freedom, can facilitate the incorporation of mutations in more constant regions. Moreover, a coevolution network involved in the conformational changes required for the activity of Env has been identified, underlining the central role played by variable regions in these processes. Besides underscoring the crucial role played by variable regions in the functionality of Env, these studies unveil a new aspect of their contribution to HIV-1 evolution

A number of viral diseases such as Hepatitis B, small pox, measles, rubella and polio have effective vaccines to control or eradicate them. HIV-1 is a lentivirus which infects human immune cells and leads to the disease called AIDS (Acquired Immuno Deficiency Syndrome). Despite much effort since the three decades of its discovery, there is no effective vaccine against HIV-1. The envelope glycoprotein of HIV-1 is the most accessible protein on the virion surface and is essential for HIV-1 infection. Thus, this protein is the primary target for HIV-1 vaccine design. However, HIV-1 has acquired numerous immune evasive mechanisms to escape from the human immune system. Various factors such as high variability of the envelope sequence, presence of immune dominant variable loop regions, extensive glycosylation which masks conserved epitopes on the envelope, weak non-covalent interactions between gp120 and gp41 subunits of the envelope and the metastable nature of the envelope hinder the development of an effective vaccine against HIV-1. Various approaches have been carried out to design immunogens based on the envelope glycoprotein but so far none of these have succeeded in elicitation of a broad neutralizing antibody response. In chapter 1, brief descriptions of the HIV-1 epidemic, structural and genomic organization of HIV-1 along with the difficulties faced and progress in the development of an HIV-1 vaccine are described. HIV-1 envelope glycoprotein (Env) is a trimer of gp120-gp41 heterodimers. The gp41 subunit in the native, pre-fusion trimeric Env exists in a metastable conformation and attains a stable post-fusion six helix bundle (6HB) conformation comprised of a trimer of N-heptad repeat (NHR) and C-heptad repeat (CHR) heterodimers, that drives fusion of viral and cellular membranes. The metastable nature of gp41 drives the equilibrium towards the post-fusion conformation which favours shedding of gp120 and formation of the gp41 six helix bundle remnants from the Env trimer. These dissociated products display non-neutralizing epitopes to the immune system to drive non-neutralizing antibody responses. Design and purification of Env glycoprotein in its native trimeric form is challenging due to the instability of the functional HIV-1 native Env trimer. In chapter 2, we describe our attempts to stabilize native Env trimers by incorporation of mutations at the NHR:CHR interface that disrupt the post-fusion 6HB of gp41. The mutations V570D and I573D stabilize native JRFL Env and occlude non-neutralizing epitopes to a greater extent than the previously identified I559P mutation that it is at the interface of the NHR trimers in the 6HB. The mutations prevent sCD4 induced gp120 shedding and 6HB formation. The data suggest that positions 570 and 573 are surface proximal in the native Env. Aspartic acid substitutions at these positions stabilize native trimers through destabilization of the post fusion 6HB conformation. These mutations should enhance the exposure of native Env forms to the immune system and therefore can be used to stabilize Env in a DNA vaccine format. In previous studies, a disulfide bond was engineered between gp120 and gp41 of Env to stabilize the interactions between them (SOS gp140). An I559P mutation was also introduced to stabilize the native gp41 conformation in the context of disulfide engineered Env (SOSIP gp140). The purified, soluble SOSIP gp140 immunogens were trimeric and cleaved properly. However, these immunogens failed to elicit broad neutralizing responses. The SOSIP gp140 immunogens appear to be good conformational mimics of the native trimeric Env. Thus, it is important to understand the details of the conformation and antigenic nature of SOSIP Env to further assist the design of Env immunogens in a native-like conformation. In chapter 3, we expressed JRFL-SOSIP Env on the cell surface and probed with various gp120 and gp41 specific antibodies to investigate whether this Env protein mimics the native like Env conformation. We show that introduction of a disulfide bond between gp120 and gp41 perturbs the native Env conformation, though this effect is partially alleviated by furin expression. The introduction of the V570D mutation instead of the I559P mutation partially restored the native like conformation of disulfide engineered Env. Proper cleavage of the Env to gp120 and gp41 is essential for the formation of native Env conformation. Uncleaved Env attains non-native forms and binds to non-neutralizing antibodies. To overcome inefficient cleavage problems, we co-expressed gp120 and gp41 genes on separate plasmids in mammalian cells and monitored the formation of native like Env complexes on the cell surface. We observed a fraction of native-like Env complexes on the cell surface when gp120 and gp41 with the V570D mutation are co¬expressed. We also describe the expression of Env with a self-cleavable 2A peptide between gp120 and gp41-V570D. We conclude that co-expression of gp120 and gp41 to form native like Env complexes is possible. HIV-1 Env trimeric immunogens are believed to be better immunogens than monomeric gp120. The trimeric Env immunogens designed so far, elicited marginally better neutralizing antibody response than monomeric gp120. However, these immunogens failed to elicit antibodies which could neutralize multiple primary HIV-1 isolates. Thus, it is possible that these immunogens have failed to mimic the native Env conformation. Cryo-EM and crystal structures of Env suggested that three gp120 monomers are held together at the apex of the Env trimer and the V1V2 regions of each gp120 monomer contribute to this trimeric interface. It was also shown that two broadly neutralizing antibodies (PG9 and PG16) bind to quaternary epitopes formed by V1V2 regions. Based on these observations, we hypothesized that insertion of heterologous trimerization domains into V1V2 loops might help in the formation of native like gp120 trimers. In chapter 4, two different trimerization domains (6-helix bundle and foldon trimerization domains) were inserted at the V1 loop of gp120 and C1 and C5 regions of gp120 were deleted to reduce the conformational flexibility of gp120. The resulting constructs were not trimeric and lost binding to trimer specific antibodies, PG9 and PG16. Due to their large distances between N and C-termini, these trimerization domains might have altered the local conformation of V1V2 regions and destabilized gp120 trimer formation. Interestingly, introduction of a trimerization domain (hCMP) at the C-terminus of C1 and C5 deleted gp120 (gp120-hCMP-21), led to the formation of native-like trimers which bound to both PG9 and PG16 antibodies. These results suggest that it may be difficult to trimerize gp120 by insertion of heterologous trimerization domains into the V1V2 loop and that conformational integrity of the V1V2 region is essential for the formation of trimeric gp120 interface. V1V2 regions of gp120 form quaternary epitopes on the Env trimer and are target for several broadly neutralizing antibodies. Moreover, these regions are important for the formation of the gp120 trimeric interface in the Env. In chapter 4, we show that insertion of heterologous trimerization domains at the V1 loop failed to form native like gp120 trimers. To further investigate this issue, in chapter 5, we made cyclic permutants of the gp120 molecule to create new N and C-termini at the V1 or V2 loop regions. This allowed the insertion of heterologous trimerization domains at these loop regions without affecting the folding and stability of gp120. The hCMP trimerization domain was introduced at the N-terminus of cyclically permuted gp120 (V1cyc and V2cyc). The resulting cyclic permutants were trimeric and retained binding to several broadly neutralizing antibodies. These cyclic permutants showed 10-20 fold increased binding to quaternary epitope specific neutralizing antibodies PG9 and PGT 145. CD4 binding site directed broadly neutralizing antibodies b12 and VRC01 also showed increased affinities to these cyclic permutants. Immunization of guinea pigs with cyclic permutants elicited broad neutralizing antibody response to Tier-1 and Tier-2 HIV-1 isolates with substantially higher titers than the corresponding monomeric gp120 immunogens. The data demonstrate that cyclic permutation of gp120 did not affect the structural and functional properties of gp120. It is possible to elicit broadly neutralizing sera against HIV-1 using cyclically permuted gp120 trimers in small animals. Among several proposed cryo-EM tomography structures of trimeric Env, some suggested that the V1V2 loop regions of gp120 are located close to the trimer interface while some other structures suggested that the V1V2 loop regions of gp120 are located far from the trimer axis. The present study supports Env models in which the V1V2 loops are proximal to the trimer interface. This has recently been confirmed in high resolution cryo-EM and crystal structures of HIV-1 gp140 derivatives. HIV-1 Env subunit gp120 has 50% of its molecular mass comprised of glycans which shield Env from immune recognition. Env has approximately 25 glycosylation sites of which ~4 are located in the inner domain, ~7-8 in the V1/V2 and V3 loops and the rest in the outer domain (OD). Earlier reports suggested that the glycans are indispensable for proper folding of Env and a certain level of glycan coverage is essential for maintaining infectivity of the virion. In chapter 6, we investigated the effect of removal of glycans from core gp120 on the infectivity of the HIV-1 and on the recognition of Env by various broadly neutralizing antibodies (bNAbs). We mutated the glycosylation sites in core gp120 to the second most frequent amino acids based on multiple sequence alignment. Pseudoviral infectivity assays and mammalian cell surface display experiments show that in the context of gp160, all core gp120 glycans are dispensable for viral infectivity and for recognition of bNAbs. We also show that deglycosylated molecules can serve as a starting point to re-introduce epitopes for specific glycan dependent bNAbs. Several of the constructs will also be useful for epitope mapping and Env structural characterization. Glycosylation of Env is known to inhibit binding to germline precursors of known bNAbs. In this study we show that recognition of VRC01 germline-bNAb increases substantially with the progressive loss of glycans from JRFL pseudoviruses. This work has so far resulted in the following publications (mentioned in next page).

The rational design of an HIV-1 vaccine immunogen able to induce potent, cross-reactive, neutralising antibodies remains one of the single greatest challenges in the field of vaccine research today. Roughly a dozen broadly neutralising monoclonal antibodies have been isolated to date, and their epitopes represent important vaccination targets. Interestingly, apart from three that identify over-lapping epitopes in gp41, all of the broadly neutralising monoclonal antibodies target epitopes apparent on different conformations of gp120 (including the epitopes of PG9/PG16). Thus the gp120 monomer remains the most ideal template for immunogen design. Recently, epitopes in the C3-V4 region of gp120 have been shown to be major targets for early strain-specific neutralising antibodies in subtype C infected individuals. Autologous neutralising antibodies identify vulnerable sites on the envelope, and understanding the nature of antigenic “hotspots” on gp120 will help to guide rational vaccine design. This study sought to confirm in four individuals that the C3-V4 epitope was in fact apparent on monomeric gp120, and thereafter to better characterise the nature of viral escape from these antibodies. Using magnetic beads coated with one of 16 different recombinant gp120 proteins it was confirmed that the C3-V4 response was aimed at a monomer-specific epitope in all four cases. In two instances these antibodies were shown to contribute to autologous neutralisation, while in a third the existence of quaternary structure specific antibodies that could not be adsorbed with monomeric gp120 made this link impossible. In the forth instance transfer of the C3-V4 region was shown to expose a normally occluded epitope in the CD4 binding site. This research also provided evidence for other epitopes for autologous neutralising antibodies in C3, overlapping with the CD4 binding site and V5. Lastly, by introducing relevant escape mutations into the parental recombinant gp120s and then comparing the ability of these proteins to adsorb out anti-C3 antibodies, it was shown that while these mutations conferred complete resistance to neutralisation they did not prevent the antibodies from binding to their respective epitopes. The extensive characterisation of C3-related epitopes such as those described in this research should no doubt contribute to the rational design of a gp120 based vaccine immunogen aimed at eliciting broad and potent neutralising antibody responses.

Since, its discovery over three decades ago, HIV has wrecked havoc worldwide. According to the UNAIDS report 2011, at present 34 million people is living with HIV and AIDS vaccine with broadly neutralizing activity still remains elusive. The envelope glycoproteins on the virion surface, is the most accessible component to the host immune system and therefore is targeted for vaccine design. However, the virus has employed various strategies to avoid the host immune response. The extremely high rate of mutations, extensive glycosylation of the envelope glycoprotein, conformational flexibility of the envelope, has made all the efforts aimed to design a broadly neutralizing immunogen futile. In Chapter1, we briefly discuss about the structural and genomic organization of the HIV-1 along with various strategies the virus has employed to evade the immune system. We also present the progress and failures encountered in the past three decades, on the way to design protective HIV vaccine and inhibitors. On the host cell surface, HIV-1 glycoprotein gp120 binds to the cell surface receptor CD4 and leads to the fusion of viral and host cellular membranes. CD4 is present on the surface of T-lymphocytes. It consists of a cytoplasmic tail, one transmembrane region, and four extracellular domains, D1−D4. sCD4 has been used as an entry inhibitor against HIV-1. However, this molecule could not neutralize primary isolates of the virus. Previously, from our lab, we had reported the design and characterization of a construct consisting of the first two domains of CD4 (CD4D12), that binds gp120 with similar affinity as soluble 4-domain CD4 (sCD4). However, the first domain alone (CD4D1) was previously shown to be largely unfolded and had 3-fold weaker affinity for gp120 when compared to sCD4 [Sharma, D.; et al. (2005) Biochemistry 44, 16192−16202]. In Chapter 2, we describe the design and characterization of three single-site mutants of CD4D12 (G6A, L51I, and V86L) and one multisite mutant of CD4D1 (G6A/L51I/L5K/F98T). G6A, L51I, and V86L are cavity-filling mutations while L5K and F98T are surface mutations which were introduced to minimize the aggregation of CD4D1 upon removal of the second domain. All the mutations in CD4D12 increased the stability and yield of the protein relative to the wild-type protein. The mutant CD4D1 (CD4D1a) with the 4 mutations was folded and more stable compared to the original CD4D1, but both bound gp120 with comparable affinity. In in vitro neutralization assays, both CD4D1a and G6A-CD4D12 were able to neutralize diverse HIV-1 viruses with similar IC50s as 4-domain CD4. These stabilized derivatives of human CD4 are useful starting points for the design of other more complex viral entry inhibitors. Most HIV-1 broadly neutralizing antibodies are directed against the gp120 subunit of the env surface protein. Native env consists of a trimer of gp120−gp41 heterodimers, and in contrast to monomeric gp120, preferentially binds CD4 binding site (CD4bs)-directed neutralizing antibodies over non-neutralizing ones. One group of cryo-electron tomography studies have suggested that the V1V2 loop regions of gp120 are located close to the trimer interface and the other group claimed that the V1V2 loop region is far from the apex of the trimer. To further investigate the position of the V1V2 region, in the native envelope trimer, in Chapter 3, we describe the design and characterization of cyclically permuted variants of gp120 with and without the h-CMP and SUMO2a trimerization domains inserted into the V1V2 loop. h-CMP-V1cyc is one such variant in which residues 153 and 142 are the N- and C-terminal residues, respectively, of cyclically permuted gp120 and h-CMP is fused to the N-terminus. This molecule forms a trimer under native conditions and binds CD4 and the neutralizing CD4bs antibodies b12 with significantly higher affinity than wild-type gp120. It binds non-neutralizing CD4bs antibody F105 with lower affinity than gp120. A similar derivative, h-CMP-V1cyc1, bound the V1V2 loop-directed broadly neutralizing antibodies PG9 and PG16 with ~15-fold higher affinity than wild-type JRCSF gp120. These cyclic permutants of gp120 are properly folded and are potential immunogens. The data also support env models in which the V1V2 loops are proximal to the trimer interface. HIV-1 envelope (env) protein gp120 has approximately 25 glycosylation sites of which ~4 are located in the inner domain, ~7-8 in the V1/V2 and V3 variable loops and the rest in the outer domain (OD) of gp120. These glycans shield env from recognition by the host immune system and are believed to be indispensable for proper folding of gp120 and viral infectivity. However, there is no detailed study that describes whether a particular potential n-linked glycan is indispensable for folding of gp120.Therefore, in Chapter 4, using rationally designed mutations and yeast surface display (YSD), we show that glycosylation is not essential for the correct in vivo folding of OD alone or OD in the context of core gp120. Following randomization of the remaining four glycosylation sites, we isolated a core gp120 mutant, which contained a single inner domain glycan and retained yeast surface expression and broadly neutralizing antibody (bNAb) binding. Thus demonstrates that most gp120 glycans are dispensable for folding in the absence of gp41. However in the context of gp160, we show that all core gp120 glycans are dispensable for folding, recognition of bNAbs and for viral infectivity. We also show that deglycosylated molecules can serve as a starting point to re-introduce epitopes for specific glycan dependent bNAbs. Several of these constructs will also be useful for epitope mapping and env structural characterization. Glycosylation of env is known to inhibit binding to germline precursors of known bNAbs. Hence the present results inform immunogen design, clarify the role of glycosylation in gp120 folding and illustrate general methodology for design of glycan free, folded protein derivatives. On the virion surface env glycoproteins gp120 and gp41 interact via non-covalent interactions and form trimers of heterodimers. Upon binding cell surface receptor CD4 and co-receptor CCR5/CXCR4, gp120 and gp41 undergo a lot of conformational changes, which ultimately lead to the fusion of viral and cellular membranes by formation of six-helix bundle in gp41. High resolution structural information is available for core gp120 and post-fusion six-helix bundle conformation of gp41. However, the structural information about the native gp120:gp41 interface in the native trimer is lacking. In Chapter 5, we describe the design and characterization of various single chain derivatives of gp120 inner doamin and gp41. Among the designed constructs, gp41-id2b is folded but is a mixture of dimer and monomer under native conditions. To facilitate, trimer formation, two trimerization domains (h-CMP and Foldon) were individually fused to the N-terminus of gp41-id2b to generate h-CMP-gp41-id2b and Foldon-gp41-id2b. Although, these molecules were proteolytically more stable than gp41-id2b, they did not form trimer under native conditions. All the single chain derivatives were designed based on the crystal structure of gp120, which was devoid of C1 and C5 domains (PDBID 1G9M). A new set of constructs to mimic the native gp120:gp41 interface will be designed and characterized based on the recently solved crystal structure of gp120 with the C1 and C5 domains (PDBID 3JWD and 3JWO). Helix-helix interactions are fundamental to many biological signals and systems, found in homo- or hetero-multimerization of signaling molecules as well as in the process of virus entry into the host. In HIV, virus-host membrane fusion during infection is mediated by the formation of six helix bundle (6HB) from homotrimers of gp41, from which a number of synthetic peptides have been derived as antagonists of virus entry. Yeast surface two-hybrid (YS2H) system is a platform, which is designed to detect protein-protein interactions occurring through a secretory pathway. In Chapter 6, we describe the use of aYS2H system, to reconstitute 6HB complex on the yeast surface and delineate the residues influencing homo-oligomeric and hetero-oligomeric coiled-coil interactions. Hence, we present YS2H as a platform for facile characterization of hetero-oligomeric interactions and design of antagonistic peptides for inhibition of HIV and many other enveloped viruses relying on membrane fusion for infection, as well as cellular signaling events triggered by hetero-oligomeric coiled coils. However, using this YS2H platform, the native hetero-oligomeric complex of gp120 and gp41 could not be captured. In Appendix 1, we report cloning, expression and purification of PΔGgp120 and ΔGgp120 from methylotrophic yeast Pichia pastoris. PΔGgp120 was purified as a secreted protein. However, in electrophoretic analyses the molecule ran as a heterogeneous smear. Further optimization of the purification protocol and biophysical characterizations of this molecule will be performed in future. In Appendix 2, gp41 variants were expressed on the yeast cell surface as a C-terminally fused protein and its interaction with externally added gp120 was monitored by FACS. The surface expression of the gp41 constructs was poor and they did not show any interaction with gp120.

碩士
國防醫學院
生物及解剖學研究所
87
The assembly of Human Immunodeficiency Virus (HIV) particles occurred at the plasma membrane of infected cells. However, mechanisms of virus assembly and budding are still unclear. The Gag polyproteins are cleaved to yield three major structural proteins arranged in the following order: NH2-membrane-associated matrix protein (MA)-capsid protein (CA)-Nucleocapsid protein (NC)-COOH. Immunoelectron microscopic studies have shown that the HIV P17MA protein (MA), is a component of the envelope-associated icosadeltahedral capsid that lines the inner surface of the viral envelope. At early stage, the mature MA dissociates from the plasma membrane and participates in the nuclear targeting process. During viral assembly, the MA domain of Pr55gag (Gag) promotes membrane targeting, and interacts with the viral envelope proteins (Env) at the cell surface, which is essential for the formation of viral particles. Previews studies showed Env could determine the site where virus releases. To investigate the factors that determine the transfer of MA to the cell membrane, subcellular organelle membrane or nucleus membrane, and whether Env protein effects the distribution of the MA and Gag, the following recombination were prepared. We prepared eight recombined constructs: Gag, Pr55gag+pol (GPG), MA, Pr55gag+Env, GPG+Env, MA+Env, MA deletion (39G1)+Env and pTM3 to transfect/infect Jurkat cells for confocal microscopic and quantitative immunoelectron microscopic analysis. Our present data showed that (1) Relative percentage of the MA distribution in cell membrane/cell in construct co-express with Env protein is higher than constructs without Env. Similar results were obtained also for the distribution of Gag. (2) Distribution of MA and virus particles in MA-deleted construct co-expressed with Env was found to have higher frequency in cytosol than those on cell membrane. (3) Relative percentage of the MA distribution in Nucleus/cell with constructs co-express with Env protein showed significant different than constructs without Env. By combining those results together, the data suggest that Env not only plays an important role in particle budding on the plasma membrane, but also modulates the distribution of MA. Furthermore the interaction of MA and Env contributes to Gag-transportation from cytosol to cell membrane.